GlassScriptPhysician profile
Noushin Emami
NPI 1356052369
$4,162.34
in general payments reported to CMS, 2019-2025
26 companies · $2,624 in 2025
The $2,624 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $189 · 2024: $1,225 · 2025: $2,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,145 · Travel and Lodging: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,145.31 |
| Travel and Lodging | $892.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,318.63 | 2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $690.97 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $378.62 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $265.44 | 2025 | Proclaim, Freestyle Libre 3, Octrode |
| Novo Nordisk INC | $245.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $204.51 | 2024 | Repatha, Evenity, Otezla |
| Globus Medical, INC. | $162.94 | 2025 | Senza, Vyrsa V1, Omnia |
| Lilly USA, LLC | $140.66 | 2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $136.95 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $114.68 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Indivior INC. | $81.07 | 2023-2024 | Sublocade |
| Aimmune Therapeutics, INC. | $36.23 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.41 | 2024-2025 | |
| Eisai INC. | $29.15 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.56 | 2024 | Cologuard Collection Kit |
| Nalu Medical, INC. | $23.39 | 2025 | Nalu Neurostimulation System |
| Janssen Pharmaceuticals, INC | $20.34 | 2024 | Spravato |
| Vanda Pharmaceuticals INC. | $19.06 | 2023 | Hetlioz |
| Almatica Pharma LLC | $16.78 | 2025 | Teriparatide |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.61 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $16.36 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Teleflex LLC | $16.30 | 2025 | Barrigel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.28 | 2023 | Xifaxan |
| Currax Pharmaceuticals LLC | $14.87 | 2025 | Contrave |
| Nevro Corp. | $13.77 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noushin Emami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.